Clinical trials: Mesothelioma
Mesothelioma, Uveal Melanoma
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
This open-label, non-randomized study will investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA damage response pathway genes.
- Conditions
- Mesothelioma, Uveal Melanoma, Renal Cell Carcinoma, Cholangiocarcinoma
- Trial name
- NCT03207347
- Testing
- Niraparib
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Florida
Mesothelioma, Pleural Mesothelioma
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
Patients with pleural mesothelioma (PM) that cannot be surgically removed will receive standard chemotherapy (cisplatin or carboplatin and pemetrexed) given with durvalumab, a type of immunotherapy, or a treatment chosen by the…
- Conditions
- Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
- Trial name
- DREAM3R (NCT04334759)
- Testing
- Durvalumab, Standard Chemotherapy, Ipilimumab and Nivolumab
- Where
- 57 sites in United States, Australia and 1 more
- Volunteers
- 214 people
- Sponsor
- PrECOG, LLC.
Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
This trial studies how well the addition of targeted radiation therapy to surgery and the usual chemotherapy treatment works for the treatment of stage I-IIIA malignant pleural mesothelioma.
- Conditions
- Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v8, Stage IA Pleural Malignant Mesothelioma AJCC v8
- Trial name
- NCT04158141
- Testing
- Carboplatin, Cisplatin, Decortication
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- NRG Oncology
Advanced/Metastatic Solid Tumor
KZR-261 in Subjects With Advanced Solid Malignancies
A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess the safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK) of KZR-261, as well as identify the recommended Phase…
- Trial name
- NCT05047536
- Testing
- KZR-261
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Kezar Life Sciences, Inc.
Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer
A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
This is an open-label, multicenter, phase 1/2 study of BBI608 in combination with pemetrexed and cisplatin chemotherapy as a 1st line treatment for Malignant Pleural Mesothelioma (MPM).
- Trial name
- NCT02347917
- Testing
- BBI608, Pemetrexed, Cisplatin
- Where
- 2 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Pleural Mesothelioma
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
The primary objective of the study is to determine the feasibility (as determined by lack of serious adverse events) and tolerability (as determined by patient's ability to complete the study) of a multimodal lung sparing regimen…
- Trial name
- NCT00859495
- Testing
- Doxorubicin, Cisplatin, Pemetrexed
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Columbia University
Biphasic Mesothelioma, Epithelioid Mesothelioma
Pembrolizumab in Treating Patients With Malignant Mesothelioma
This phase II trial studies how well pembrolizumab works in treating patients with malignant mesothelioma, a cancer of the linings around the lungs (pleura) or abdomen (peritoneum).
- Conditions
- Biphasic Mesothelioma, Epithelioid Mesothelioma, Peritoneal Malignant Mesothelioma, Pleural Biphasic Mesothelioma
- Trial name
- NCT02399371
- Testing
- Pembrolizumab, Laboratory Biomarker Analysis, Pharmacogenomic Study
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Chicago
Mesothelioma, Adenocarcinoma of Lung
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
Background: Malignant mesothelioma is a form of cancer that develops on the protective lining that covers the body's internal organs. It most often occurs on the lining of the lungs and chest wall or the lining of the abdomen.
- Conditions
- Mesothelioma, Adenocarcinoma of Lung, Pancreatic Neoplasms
- Trial name
- NCT01362790
- Testing
- Pentostatin, Cyclophosphamide, SS1(dsFv)PE38 - lot 073I0809
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Mesothelioma
Nintedanib (BIBF 1120) in Mesothelioma
This is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin…
- Trial name
- NCT01907100
- Testing
- Nintedanib, Pemetrexed, Cisplatin
- Where
- 123 sites in United States, Argentina and 25 more
- Volunteers
- 545 people
- Sponsor
- Boehringer Ingelheim
Mesothelioma
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
Background: Treatment outcomes for people with pleural or peritoneal mesothelioma are often poor. The drug LMB-100 can attack and kill cancer cells. The drug pembrolizumab helps the immune system fight cancer.
- Trial name
- NCT03644550
- Testing
- LMB-100, Pembrolizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
This study will provide continuing availability to tazemetostat for people that have previously completed participation in a tazemetostat study, either with monotherapy (single drug treatment) or combination therapy.
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epithelioid Sarcoma (ES)
- Trial name
- TRuST (NCT02875548)
- Testing
- Tazemetostat
- Where
- 34 sites in United States, Australia and 5 more
- Volunteers
- 58 people
- Sponsor
- Epizyme, Inc.
Non-small Cell Lung Cancer, Mesothelioma
Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen
This study will test the effects of pemetrexed on mesothelioma and non-small cell lung cancer patients with fluid around their lungs or abdomen.
- Conditions
- Non-small Cell Lung Cancer, Mesothelioma, Lung Neoplasms
- Trial name
- NCT00316225
- Testing
- pemetrexed
- Where
- 3 sites in Denmark, Germany and 1 more
- Volunteers
- 31 people
- Sponsor
- Eli Lilly and Company
Malignant Pleural Mesothelioma
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
For patients with malignant pleural mesothelioma that has grown despite treatment with standard chemotherapy, no treatment has yet proven beneficial.
- Trial name
- NCT01024946
- Testing
- everolimus
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Lung Adenocarcinoma, Ovarian Cancer
CAR T Cells in Mesothelin Expressing Cancers
Phase I study to establish safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells with or without lymphodepletion.
- Conditions
- Lung Adenocarcinoma, Ovarian Cancer, Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT03054298
- Testing
- huCART-meso cells
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Pennsylvania
Metastatic Cancer, Solid Tumors
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
- Conditions
- Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer
- Trial name
- NCT02903914
- Testing
- INCB001158, Pembrolizumab
- Where
- 20 sites in United States, Italy and 2 more
- Volunteers
- 260 people
- Sponsor
- Incyte Corporation
Advanced Cancer, Advanced Solid Tumor
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
This study is an open-label, multi-arm, parallel cohort, dose validation and expansion design. The study is modular in design, allowing evaluation of the safety, efficacy and pharmacokinetics (PK) of NUC-3373 in combination with…
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer
- Trial name
- NCT05714553
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- NuCana plc
Malignant Pleural Mesothelioma
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
The main objective of the trial is to document the efficacy of NGR-hTNF administered at low dose weekly in advanced Malignant Pleural Mesothelioma patients previously treated with a pemetrexed-based chemotherapy regimen.
- Trial name
- NCT01098266
- Testing
- NGR-hTNF plus Best Investigator's Choice (BIC)
- Where
- 49 sites in United States, Belgium and 10 more
- Volunteers
- 400 people
- Sponsor
- AGC Biologics S.p.A.
Advanced Malignant Pleural Mesothelioma
Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma
This is a multi-centre non-randomised open-label phase 1 trial of pembrolizumab given in combination with SBRT to part of a pleural-based lesion in patients with unresectable MPM.
- Trial name
- MESO-PRIME (NCT04166734)
- Testing
- Pembrolizumab, Stereotactic Body Radiotherapy (SBRT)
- Where
- 2 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Mesothelioma; Lung
Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma
This is an open-label, non-randomized, phase II, single arm, multi-center controlled clinical trial. 47 patients will be enrolled in this trial to determine the efficacy and safety of Bintrafusp alfa (M7824) in advanced malignant…
- Trial name
- BIMES (NCT05005429)
- Testing
- Bintrafusp alfa
- Where
- 15 sites in Spain
- Volunteers
- 47 people
- Sponsor
- Fundación GECP